The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

BACKGROUND: Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not for women of child-bearing potential because of teratogenicity. Levetiracetam is increasingly prescribed for these patient populations despite scarcity...

Descripción completa

Detalles Bibliográficos
Autores principales: Marson, Anthony, Burnside, Girvan, Appleton, Richard, Smith, Dave, Leach, John Paul, Sills, Graeme, Tudur-Smith, Catrin, Plumpton, Catrin, Hughes, Dyfrig A, Williamson, Paula, Baker, Gus A, Balabanova, Silviya, Taylor, Claire, Brown, Richard, Hindley, Dan, Howell, Stephen, Maguire, Melissa, Mohanraj, Rajiv, Smith, Philip E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047813/
https://www.ncbi.nlm.nih.gov/pubmed/33838758
http://dx.doi.org/10.1016/S0140-6736(21)00246-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047813/
https://www.ncbi.nlm.nih.gov/pubmed/33838758
http://dx.doi.org/10.1016/S0140-6736(21)00246-4

Ejemplares similares